Pharmacogenetic Dosing of Warfarin
Stroke, Venous Thrombosis, Atrial Fibrillation
About this trial
This is an interventional treatment trial for Stroke
Eligibility Criteria
Inclusion Criteria:
- Patients must give their informed consent and complete the case report form.
- Patients must be over the age of 20.
- Patients have clinical indications for warfarin therapy but do not have any prior warfarin treatment.
Exclusion Criteria:
- Patients who did not complete the informed consent form or the CRF
- Patients who are less than the age of 20.
- Patients who had prior or is currently on warfarin treatment.
- Patients who have hemorrhagic tendencies or hemorrhagic diseases defined as copious bleeding caused by viral or bacterial infections; cancer and hepatic dysfunction defined as GOP and GPT values three times higher than normal value
- Patients who has Vitamin K deficiency
- Female patients who is currently pregnant
Sites / Locations
- Kaohsiung Medical University
- China Medical University Hospital
- Chang Gung Memorial Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Experimental
Experimental
Standard of care dosing for warfarin
Genotype-guided dosingTaiwan algorithm for warfarin
Genotype-guided dosing IWPC algorithm for warfarin
Loading dose (5mg) of warfarin for the first 3 days of treatment. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).
Initial loading dosing of warfarin for the first 3 days of treatment will be determined by the Taiwan algorithm that uses clinical and genetic information. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).
Initial loading dosing of warfarin for the first 3 days of treatment will be determined by the IWPC algorithm that uses clinical and genetic information. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).